Dear Doctor Anaplastic lymphoma kinase positive (ALK+) lung cancer is a relatively rare subtype, occurring in about 1 in 25 cases of non-small-cell lung cancer (NSCLC). Inhibitors designed for the ALK gene, such as crizotinib, alectinib, brigatinib, and lorlatinib, have demonstrated significant potential in NSCLC treatment. 1, 2 We would like to hear your thoughts on the current treatment practices and your preferred management approach for NSCLC patients. Here’s a survey on this topic that’ll take only two minutes to fill!
Do share your experience and insights with us. ##References## https://lcfamerica.org/lung-cancer-info/types-lung-cancer/alk-positive-lung-cancer/ Solomon BJ, Bauer TM, Mok TSK, Liu G, Mazieres J, de Marinis F, Goto Y, Kim DW, Wu YL, Jassem J, López FL, Soo RA, Shaw AT, Polli A, Messina R, Iadeluca L, Toffalorio F, Felip E. Efficacy and safety of first-line…
